Navana Pharmaceuticals PLC (DSE:NAVANAPHAR)
Bangladesh · Delayed Price · Currency is BDT 67.60
+1.20 (1.81%)
At close: Sep 3, 2026
Navana Pharmaceuticals Ratios and Metrics
Market cap in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 7,261 | 5,403 | 9,377 | 12,546 | - | - | |
Market Cap Growth | 6.12% | -42.38% | -25.26% | - | - | - |
Enterprise Value | 10,909 | 10,136 | 13,845 | 15,739 | - | - |
Last Close Price | 67.60 | 48.90 | 82.67 | 108.87 | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
PE Ratio | 12.06 | 11.08 | 23.18 | 35.15 | - | - |
PS Ratio | 0.69 | 0.61 | 1.36 | 2.20 | - | - |
PB Ratio | 1.36 | 1.11 | 2.06 | 2.87 | - | - |
P/TBV Ratio | 1.36 | 1.11 | 2.06 | 2.87 | - | - |
P/FCF Ratio | 3.83 | 3.74 | - | - | - | - |
P/OCF Ratio | 3.06 | 2.98 | 13.26 | 64.76 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
EV/Sales Ratio | 1.03 | 1.15 | 2.01 | 2.76 | - | - |
EV/EBITDA Ratio | 6.13 | 5.91 | 11.90 | 16.29 | - | - |
EV/EBIT Ratio | 7.31 | 7.01 | 13.96 | 20.83 | - | - |
EV/FCF Ratio | 5.76 | 7.02 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Debt / Equity Ratio | 0.74 | 0.96 | 1.18 | 0.99 | 0.87 | 0.45 |
Debt / EBITDA Ratio | 2.20 | 2.63 | 4.46 | 4.48 | 4.09 | 3.42 |
Debt / FCF Ratio | 2.07 | 3.22 | - | - | - | - |
Net Debt / Equity Ratio | 0.69 | 0.91 | 1.10 | 0.85 | 0.80 | 0.44 |
Net Debt / EBITDA Ratio | 2.11 | 2.58 | 4.33 | 3.85 | 4.13 | 3.69 |
Net Debt / FCF Ratio | 1.93 | 3.07 | -8.05 | -2.65 | -2.40 | -3.67 |
Asset Turnover | 0.93 | 0.78 | 0.66 | 0.68 | 0.78 | 0.75 |
Inventory Turnover | 2.54 | 2.26 | 1.96 | 2.28 | 2.47 | 2.27 |
Quick Ratio | 0.31 | 0.26 | 0.21 | 0.26 | 0.19 | 0.31 |
Current Ratio | 0.91 | 0.86 | 0.87 | 0.99 | 0.88 | 1.15 |
Return on Equity (ROE) | 11.90% | 10.35% | 9.06% | 9.09% | 8.07% | 6.31% |
Return on Assets (ROA) | 8.17% | 7.94% | 5.93% | 5.67% | 5.80% | 4.52% |
Return on Invested Capital (ROIC) | 12.31% | 11.22% | 8.67% | 8.18% | 7.12% | 5.31% |
Return on Capital Employed (ROCE) | 25.40% | 26.70% | 19.80% | 16.00% | 15.00% | 9.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Earnings Yield | 8.35% | 9.03% | 4.32% | 2.84% | - | - |
FCF Yield | 26.08% | 26.73% | -6.67% | -11.19% | - | - |
Dividend Yield | 2.11% | 2.86% | 1.69% | 1.19% | - | - |
Payout Ratio | 8.47% | 8.52% | 33.83% | 31.70% | - | - |
Buyback Yield / Dilution | -0.74% | - | -8.05% | -23.91% | - | - |
Total Shareholder Return | 1.36% | 2.86% | -6.36% | -22.72% | - | - |